UK Markets closed
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • FTSE 250

    20,961.31
    -334.92 (-1.57%)
     
  • AIM

    1,163.26
    -10.13 (-0.86%)
     
  • GBP/EUR

    1.1609
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.4316%)
     
  • BTC-GBP

    35,030.59
    -1,045.40 (-2.90%)
     
  • CMC Crypto 200

    969.86
    +26.69 (+2.83%)
     
  • S&P 500

    3,813.56
    +45.09 (+1.20%)
     
  • DOW

    31,281.48
    +357.34 (+1.16%)
     
  • CRUDE OIL

    66.21
    +2.38 (+3.73%)
     
  • GOLD FUTURES

    1,701.30
    +0.60 (+0.04%)
     
  • NIKKEI 225

    28,864.32
    -65.79 (-0.23%)
     
  • HANG SENG

    29,098.29
    -138.50 (-0.47%)
     
  • DAX

    13,920.69
    -135.65 (-0.97%)
     
  • CAC 40

    5,782.65
    -48.00 (-0.82%)
     

Global Biosimilars Market (2020 to 2026) - Products, Applications and Regulations - ResearchAndMarkets.com

·5-min read

The "Global Biosimilars Market - Products, Applications and Regulations" report has been added to ResearchAndMarkets.com's offering.

The global market for Biosimilars is dominated by Oncology, estimated at US$5.4 billion (38.6% share) in 2020, which is anticipated to post the slowest CAGR of 29% between 2020 and 2026 and reach a projected US$24.8 billion by 2026.

Due to the COVID-19 Pandemic, telehealth and tele-detailing (also called remoter detailing or web calls) have set forth that allow a biosimilars companies' commercialization branch to have a wide range with less few reps. Also, the fluidity of the labor market is another new dynamic allowing for a greater diversity of commercialization build-out models. These new dynamics greatly change how companies should be building models of commercialization that also has vast implications for potential BD partnerships.

The solution to 'build versus buy' is no longer driven by the size, scale, and cost of a sales force leading to outdated product P&L's. However, a hybrid solution that a partial build plus skilled, experienced contractors plus CSO for sales reps will be the optimal solution. This hybrid model could allow for greater biosimilar uptake and more efficient uptake.

Companies Mentioned

  • 3SBio, Inc

  • AbbVie Inc

  • Allergan

  • AMEGA Biotech

  • Amgen Inc.

  • Apotex, Inc.

  • AXXO GmbH

  • BIOCAD

  • Biocon Ltd

  • Biogen, Inc.

  • Bioton S.A.

  • Boehringer

  • Boehringer Ingelheim

  • C.H. Boehringer Sohn AG & Co., KG.

  • Celltrion, Inc.

  • Coherus Biosciences

  • Creative Biomart, Inc.

  • Dong-A Socio Group

  • Dr. Reddy's Laboratories Ltd.

  • Eli Lilly and Company

  • F. Hoffmann-La Roche Ltd

  • Fresenius Kabi AG

  • And Many More

Research Findings & Coverage

  • Global Biosimilars market is analyzed in this report with respect to key product types and major therapeutic areas

  • The study exclusively analyzes the market for each product type and therapeutic area of Biosimilars by all major geographic regions/countries globally

  • mAbs - All the Rage in Biosimilars' New Wave

  • Patent Expirations of Major Biologics Leads Way for Biosimilars

  • Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation

  • Availability of Biosimilar May Affect Biologic Drug Pricing

  • Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments

  • Major companies profiled - 36

  • The industry guide includes the contact details for 155 companies

Analysis Period, Units and Growth Rates

  • The report reviews, analyzes and projects the global Biosimilars market for the period 2017-2026 in terms of US$ and the compound annual growth rates (CAGRs) projected from 2019 through 2026

Key Topics Covered:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION

1.1 Product Outline

1.1.1 Biosimilars Defined

1.1.2 Backdrop

1.1.3 The Biologics Price Competition and Innovation Act (BPCI Act)

1.1.3.1 Data Exclusivity

1.1.4 Steps Involved in Biosimilar Synthesis

1.1.5 Key Regulatory Authorization Pathway - Synopsis

1.1.6 Biosimilars Types

1.1.6.1 Monoclonal Antibodies (mAB or moAB)

1.1.6.2 Erythropoietin (EPO)

1.1.6.3 Granulocyte Colony-Stimulating Factor (G-CSF)

1.1.6.4 Insulin

1.1.6.5 Interferons

1.1.6.6 Human Growth Hormone

1.1.6.7 Other Biosimilars

1.1.7 Biosimilars Therapeutic Areas

1.1.7.1 Oncology

1.1.7.2 Autoimmune Diseases

1.1.7.3 Blood Disorders

1.1.7.4 Growth Hormone Deficiency (GHD)

1.1.7.5 Infectious Diseases

2. REGULATORY LANDSCAPE

2.1 The United States

2.1.1 Scientific Considerations in Demonstrating Biosimilarity to a Reference Product

2.1.2 Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product

2.1.3 Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009

2.1.4 FDA Issues New Regulatory Updates in 2020

2.2 European

2.3 The World Health Organization (WHO)

2.4 Canada

2.5 South Korea

2.6 China

2.7 India

2.8 Japan

2.9 Mexico

2.10 Brazil

2.11 Argentina

3. KEY MARKET TRENDS

3.1 mAbs - All The Rage In Biosimilars' New Wave

3.1.1 The Buildup to the Biosimilar Industry

3.1.2 Biosimilars of mAbs Approved: A Sneak Preview

3.2 Patent Expirations of Major Biologics Leads Way for Biosimilars

3.3 Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation

3.4 Availability of Biosimilar May Affect Biologic Drug Pricing

3.5 Asia-Pacific Witnessing a Boom of Biosimilars

4. RECENT BIOSIMILARS APPROVALS

5. KEY GLOBAL PLAYERS

6. KEY BUSINESS AND PRODUCT TRENDS

  • AbbVie Inc and Frontier Collaborate on Novel Therapies and E3 Degraders

  • Eli Lilly and UHG Collaborate on Bamlanivimab (LY-CoV555) Antibody Study

  • Merck Receives FDA Review Acceptance for KEYTRUDA (pembrolizumab) Plus Chemotherapy

  • Samsung Bioepis and Biogen File U.S FDA Acceptance of SB11 Biosimilar

  • EMA Approves Roche's Xofluza Biosimilar

  • Genor's New Drug Application for GB242 Infliximab Biosimilar is Under Review by NMPA

  • NeuClone Discloses it's Stelara Biosimilar Candidate Clinical Trials

  • And more!

7. GLOBAL MARKET OVERVIEW

7.1 Global Biosimilars Market Overview by Product Type

7.2 Global Biosimilars Market Overview by Therapeutic Area

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

8. EUROPE

9. NORTH AMERICA

10. ASIA-PACIFIC

11. REST OF WORLD

PART C: GUIDE TO THE INDUSTRY

PART D: ANNEXURE

For more information about this report visit https://www.researchandmarkets.com/r/90p1a0

View source version on businesswire.com: https://www.businesswire.com/news/home/20210122005245/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900